Expression of PCNA and CD44v6 in human hepatocellular carcinoma and its clinical significance
张震生, 王海东, 周正, 张远春, 贾振庚, 花瞻
Abstract
张震生, 王海东, 周正, 张远春, 贾振庚, 花瞻
Abstract
目的探讨PCNA、CD44v6在肝细胞癌(HCC)组织的表达及其临床病理意义.方法采用PCNA、CD44v6单克隆抗体,对83例HCC标本进行免疫组化染色.结果PCNA、CD44v6在HCC的阳性率分别为87.95%和53.01%.PCNA在EdmondsonⅠ、Ⅱ、Ⅲ、Ⅳ级的阳性率分别为01).CD44v6在转移组的高表达率为00%,有显著性差异(P<0.42.86%、89.47%一92.86%、139.29%.明显高于无转移组(10.91%,P<0.01).CD44v6在包膜完整组和不完整组的阳性率分别为35.42%和77.14%,有显著性差异(P<0.01).CD44v6阳性病人的生存期明显短于CD44v6阴性病人(P<0.05).PCNA和CD44v6在HCC的表达呈正相关.结论PCNA、CD44v6有望成为预测HCC发生、发展、转移、预后的生物学指标.
A significance statement is not available in the OpenAlex record.
A contribution statement is not available in the OpenAlex record.
Method details are not available in the OpenAlex metadata.
Findings are not separately available in the OpenAlex metadata.
Limitations are not available in the OpenAlex metadata.
Application details are not available in the OpenAlex metadata.
目的探讨PCNA、CD44v6在肝细胞癌(HCC)组织的表达及其临床病理意义.方法采用PCNA、CD44v6单克隆抗体,对83例HCC标本进行免疫组化染色.结果PCNA、CD44v6在HCC的阳性率分别为87.95%和53.01%.PCNA在EdmondsonⅠ、Ⅱ、Ⅲ、Ⅳ级的阳性率分别为01).CD44v6在转移组的高表达率为00%,有显著性差异(P<0.42.86%、89.47%一92.86%、139.29%.明显高于无转移组(10.91%,P<0.01).CD44v6在包膜完整组和不完整组的阳性率分别为35.42%和77.14%,有显著性差异(P<0.01).CD44v6阳性病人的生存期明显短于CD44v6阴性病人(P<0.05).PCNA和CD44v6在HCC的表达呈正相关.结论PCNA、CD44v6有望成为预测HCC发生、发展、转移、预后的生物学指标.
Key concepts: Hepatocellular carcinoma, Proliferating cell nuclear antigen, Cancer research, Expression (computer science), Medicine, Immunohistochemistry, Pathology, Computer science